Quadrature Capital Ltd Has $34.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Quadrature Capital Ltd decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 61,050 shares of the biopharmaceutical company’s stock after selling 9,399 shares during the period. Quadrature Capital Ltd owned approximately 0.06% of Regeneron Pharmaceuticals worth $34,306,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership raised its position in shares of Regeneron Pharmaceuticals by 3,076.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 192,584 shares of the biopharmaceutical company’s stock worth $108,284,000 after purchasing an additional 186,521 shares during the period. Invesco Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after purchasing an additional 408,649 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $744,000. Sei Investments Co. grew its position in shares of Regeneron Pharmaceuticals by 39.2% in the 3rd quarter. Sei Investments Co. now owns 45,033 shares of the biopharmaceutical company’s stock valued at $25,316,000 after purchasing an additional 12,692 shares during the period. Finally, Mackenzie Financial Corp increased its stake in Regeneron Pharmaceuticals by 26.8% during the 3rd quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock worth $72,321,000 after purchasing an additional 27,205 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $746.61 on Friday. The business’s 50-day simple moving average is $770.34 and its 200 day simple moving average is $692.97. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The firm has a market capitalization of $78.93 billion, a PE ratio of 17.96, a PEG ratio of 2.08 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Evercore increased their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday, January 22nd. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Finally, Canaccord Genuity Group upped their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.